SCHEMBL5008073

SCHEMBL5008073

CCOc1ccc(-n2c(C)c(C(C)=O)c(C(C)=O)c2C)c([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
GAA P10253 2/20 0.56
CYP1A2 P05177 2/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52
MAPT P10636 7/20 0.49
SMN1; SMN2 Q16637 7/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MAPK1 P28482 2/20 0.49
LMNA P02545 1/20 0.48
KMT2A Q03164 7/20 0.46
MEN1 O00255 5/20 0.46
PKM P14618 2/20 0.46
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 1/20 0.45
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5005313 0.82 ALDH1A1 (0.65) ALDH1A1GAAMAPTSMN1; SMN2NPSR1
SCHEMBL5005746 0.82 ALDH1A1 (0.72) ALDH1A1GAACYP1A2CYP3A4CYP2D6
SCHEMBL5009875 0.81 ALDH1A1 (0.63) ALDH1A1GAACYP3A4MAPTSMN1; SMN2
SCHEMBL13993263 0.81 CACNA2D1 (0.54) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL5005545 0.80 CACNA2D1 (0.53) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5009835 0.79 ALDH1A1 (0.60) ALDH1A1GAAMAPTSMN1; SMN2NPSR1
SCHEMBL12897966 0.76 MAPT (0.57) ALDH1A1GAACYP1A2CYP3A4CYP2D6
SCHEMBL5008132 0.73 ALDH1A1 (0.57) ALDH1A1GAAMAPTSMN1; SMN2NPSR1
SCHEMBL11648461 0.73 ALDH1A1 (0.68) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3721960 0.72 MAPT (0.64) ALDH1A1GAACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465730-B2 Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds MERCK & CO. INC. (US) 2008-12-16 US disclosed
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds MERCK SHARP & DOHME CORP. 2006-07-13 US disclosed
EP-1539168-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO(3,4-D)PYRIDAZINE COMPOUNDS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2004006836-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS MERCK & CO., INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds GRIN2C, CACNA1C, CACNG4 ALDH1A1 1590/4885GAA 1591/4885CYP1A2 1552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.